Drug Trial Radar · NCT03345914
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
Last checked: Nov 19, 2026Latest source record: Aug 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
367
Actual
Start
Nov 17, 2017
Primary completion
Jun 20, 2019
Study completion Sep 10, 2019
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Nov 17, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 11 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective of the trial is to demonstrate the efficacy of dupilumab administered concomitantly with topical corticosteroids (TCS) in participants ≥6 years to \<12 years of age with severe atopic dermatitis (AD). The secondary objective is to assess the safety of dupilumab administered concomitantly with TCS in patients ≥6 years to \<12 years of age with severe AD.
Conditions
- Dermatitis, Atopic
Interventions
DupilumabDrug
Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous (SC)
Matching PlaceboDrug
Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous (SC)
Background Treatment: Topical CorticosteroidsOther
All participants are required to initiate treatment with a medium potency TCS using a standardized regimen. It is recommended that participants use triamcinolone acetonide 0.1% cream, fluocinolone acetonide 0.025% cream, or clobetasone butyrate 0.05%.
Background Treatment: MoisturizersOther
All participants should apply moisturizers throughout the study. All types of moisturizers are permitted, but participants may not initiate treatment with prescription moisturizers. Participants may continue using stable doses of such moisturizers if initiated before the screening visit.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Investigator's Global Assessment (IGA) 0 or 1 at Week 16Time frame: Week 16
Locations
61 sites in 6 countries. Site status is shown where the registry gives one.
Regeneron Research Site
Birmingham, Alabama
Regeneron Research Site
Gilbert, Arizona
Regeneron Research Site
Bakersfield, California
Regeneron Research Site
Long Beach, California
Regeneron Research Site
Mission Viejo, California
Regeneron Research Site
Rolling Hills Estates, California
Regeneron Research Site
San Diego, California
Regeneron Research Site
Denver, Colorado
Regeneron Research Site
Coral Gables, Florida
Regeneron Research Site
Tampa, Florida
Regeneron Research Site
Tampa, Florida
Regeneron Research Site
Macon, Georgia
Regeneron Research Site
Sandy Springs, Georgia
Regeneron Research Site
Chicago, Illinois
Regeneron Research Site
Normal, Illinois
Regeneron Research Site
Rockville, Maryland
Regeneron Research Site
Ypsilanti, Michigan
Regeneron Research Site
Minneapolis, Minnesota
Regeneron Research Site
St Louis, Missouri
Regeneron Research Site
Forest Hills, New York
Regeneron Research Site
New York, New York
Regeneron Research Site
Rochester, New York
Regeneron Research Site
Gahanna, Ohio
Regeneron Research Site
Portland, Oregon
Regeneron Research Site
Philadelphia, Pennsylvania
Regeneron Research Site
Charleston, South Carolina
Regeneron Research Site
North Charleston, South Carolina
Regeneron Research Site
Bellaire, Texas
Regeneron Research Site
San Antonio, Texas
Regeneron Research Site
Norfolk, Virginia
Regeneron Research Site
Seattle, Washington
Regeneron Research Site
Calgary, Alberta, Canada
Regeneron Research Site
Markham, Ontario, Canada
Regeneron Research Site
Peterborough, Ontario, Canada
Regeneron Research Site
Montreal, Quebec, Canada
Regeneron Research Site
Kutná Hora, Czechia
Regeneron Research Site
Ústí nad Labem, Czechia
Regeneron Research Site
Bad Bentheim, Germany
Regeneron Research Site
Hamburg, Germany
Regeneron Research Site
Munich, Bavaria, Germany
Showing 40 of 61 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.